The Efficacy of a Hansenula-Derived 20 kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C

摘要: Pending the emergence and approval of an effective interferon-free regimen, pegylated interferon will remain integral part treatment genotype 4 hepatitis C virus (HCV). A new 20 kDa has been developed in a cost-saving fungal-based system is commercialized Egypt at quarter to third price conventional interferon. We hereby test efficacy safety this novel One hundred ninety-three consecutive treatment-naive patients with HCV were treated using following regimen: subcutaneous 160 μg once weekly plus oral ribavirin 1,000 or 1,200 mg daily (based on body weight <75 kg ≥75 kg, respectively) for 48 weeks. sustained virological response (SVR) 51% was achieved. Interim responses included rapid (RVR): 54%, early (EVR): 78% (complete EVR: 71%, partial 7%), end response: 63%. The most common adverse events ...